Loading...
•
Jun 30, 2020
Amneal Q2 2020 Earnings Report
Amneal's financial performance was strong in the second quarter of 2020, with increased revenue and adjusted EBITDA.
Key Takeaways
Amneal Pharmaceuticals reported a net revenue of $465 million for Q2 2020, a 15% increase compared to Q2 2019. The company's GAAP net loss was $(12) million, and adjusted EBITDA was $101 million. Adjusted diluted EPS was $0.13.
Net revenue for Q2 2020 reached $465 million, a 15% increase year-over-year.
GAAP net loss for Q2 2020 was $(12) million; diluted loss per share was $(0.08).
Adjusted EBITDA for Q2 2020 increased by 9% to $101 million.
The company is maintaining its full year 2020 financial outlook.
Revenue by Segment
Forward Guidance
Amneal is maintaining its previously provided 2020 guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...